534 related articles for article (PubMed ID: 33746969)
1. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
D'Souza C; Prince HM; Neeson PJ
Front Immunol; 2021; 12():632399. PubMed ID: 33746969
[TBL] [Abstract][Full Text] [Related]
2. [Current status and future prospects of immunotherapy for multiple myeloma].
Imai Y
Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Görgün G; Calabrese E; Soydan E; Hideshima T; Perrone G; Bandi M; Cirstea D; Santo L; Hu Y; Tai YT; Nahar S; Mimura N; Fabre C; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Oct; 116(17):3227-37. PubMed ID: 20651070
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Hayashi T; Hideshima T; Akiyama M; Podar K; Yasui H; Raje N; Kumar S; Chauhan D; Treon SP; Richardson P; Anderson KC
Br J Haematol; 2005 Jan; 128(2):192-203. PubMed ID: 15638853
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Quach H; Ritchie D; Stewart AK; Neeson P; Harrison S; Smyth MJ; Prince HM
Leukemia; 2010 Jan; 24(1):22-32. PubMed ID: 19907437
[TBL] [Abstract][Full Text] [Related]
9. Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma.
Bullok KF; Sippel C; Schmidt-Wolf IG
Hematol Oncol; 2016 Dec; 34(4):208-216. PubMed ID: 25784599
[TBL] [Abstract][Full Text] [Related]
10. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Guo H; Yang J; Wang H; Liu X; Liu Y; Zhou K
Front Immunol; 2022; 13():1017990. PubMed ID: 36311747
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC
Blood; 2001 Jul; 98(1):210-6. PubMed ID: 11418482
[TBL] [Abstract][Full Text] [Related]
12. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Casneuf T; Adams HC; van de Donk NWCJ; Abraham Y; Bald J; Vanhoof G; Van der Borght K; Smets T; Foulk B; Nielsen KC; Rusbuldt J; Axel A; Lysaght A; Ceulemans H; Stevenaert F; Usmani SZ; Plesner T; Avet-Loiseau H; Nijhof I; Mutis T; Schecter JM; Chiu C; Bahlis NJ
Leukemia; 2021 Feb; 35(2):573-584. PubMed ID: 32457357
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
Bisht K; Fukao T; Chiron M; Richardson P; Atanackovic D; Chini E; Chng WJ; Van De Velde H; Malavasi F
Cancer Med; 2023 Oct; 12(20):20332-20352. PubMed ID: 37840445
[TBL] [Abstract][Full Text] [Related]
15. [Immunomodulatory effects of lenalidomide].
Handa H; Saitoh T; Murakami H
Nihon Rinsho; 2015 Jan; 73(1):156-61. PubMed ID: 25626322
[TBL] [Abstract][Full Text] [Related]
16. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
17. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
Front Immunol; 2018; 9():704. PubMed ID: 29706958
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
20. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
Tamura H
Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
